Active, Not Recruiting
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
- Conditions
- Adenoviridae Infections, DNA Virus Infections, Infections, +10 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
- Northwell Heatlh/Lenox Hill Hospital New York, United States
- Docrates Cancer Center Helsinki, Finland